Safety, Target Engagement and Effects of Bosutinib in Dementia with Lewy Bodies
Objective: To investigate the safety, biomarkers effects and determine the lowest effective dose of Bosutinibin Dementia with Lewy Bodies (DLB) Background: The effects of bosutinib,…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…Can membrane association of α-synuclein aggregates lead to stress in the astrocytic endoplasmic reticulum?
Objective: To study the association extracellularly added wildtype-WT and A30P/A53T mutant α-synuclein aggregates with the astrocytic membrane and to evaluate the effect of these peptides…No evidence for the impact of SNCA rs356219 on Parkinson’s disease progression
Objective: To replicate findings from previous studies reporting an association between the α-synuclein (SNCA) rs356219 genetic variant and progression to key outcomes in Parkinson’s disease…Early Synucleinopathy is Associated with Differential Regulation of Neurotransmission and Immune Related Genes
Objective: Identification of gene expression changes in the rat substantia nigra pars compacta (SNpc) associated with early alpha-synuclein (a-syn) inclusion formation. Background: Accumulation of intracellular…Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs
Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…The overexpression of a-SYN leads to a differential process of mitophagy in neurons and atrocytes
Objective: To determine the role of the different mitophagy pathways involved in PD, a key question that is still unresolved. We will investigate whether a-synuclein…The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation
Objective: Lu AF82422 is a human IgG1 monoclonal antibody that binds all known forms of alpha-synuclein (aSyn), including monomeric, aggregated and truncated. Data are presented…A mouse model to test the cortical pathogenic theory of Parkinson’s disease
Objective: To develop a mouse model of chronic corticostriatal overactivity and increase expression of corticostriatal alpha-synuclein. Background: Parkinson’s disease typically has a focal motor onset1,…DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease
Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 51
- Next Page »